
Immix Biopharma rose 94.1% from $4.04 to $7.84, ahead of the S&P 500's +13.3%. Its worst day was Mar 18 (−14.9%), and its low came Nov 20 at $4.02.
Nov 17, 2025 – Nov 13, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Immix Biopharma closed at its lowest level of the year, 0.5% below where the year started.
−5.0% · S&P 500 −1.5%
Immix Biopharma shares rose 16.6%, while the S&P 500 rose 0.1%.
+16.6%, the year's best day · S&P 500 +0.1%
Story events cover the past 12 months · Times ET
Immix Biopharma shares fell 14.9%, while the S&P 500 fell 1.4%.
−14.9%, the year's worst day · S&P 500 −1.4%
EPS of $-0.28 missed the $-0.16 estimate on $0.00 revenue.
−2.1% · S&P 500 −1.8%
EPS of $-0.18 beat the $-0.21 estimate on $0.00 revenue.
+2.2% · S&P 500 +0.8%
Immix Biopharma shares rose 15.0%, while the S&P 500 fell 0.5%.
+15.0% · S&P 500 −0.5%
Immix Biopharma shares fell 14.1%, while the S&P 500 fell 0.2%.
−14.1% · S&P 500 −0.2%
EPS of $-0.18 missed the $-0.17 estimate on $0.00 revenue.
+4.2% · S&P 500 0.0%
Immix Biopharma closed at its highest level of the year, 258.2% above where the year started.
+6.3% · S&P 500 +0.3%
EPS of $-0.19 missed the $-0.18 estimate on $0.00 revenue.
−2.9% · S&P 500 −0.4%
Where it ended: a close of $7.84 on Nov 13, 2026.
Nothing in the past 12 months.
All IMMX dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for IMMX and SPY from Benzinga historical bars. Not investment advice.